Caplin Point rallies upon receiving USFDA approval for hypotension drug

Pratik Shastri
/ Categories: Trending, DSIJ News
Caplin Point rallies upon receiving USFDA approval for hypotension drug

Caplin Point Laboratory's stock traded higher by over 9 per cent on Friday after its subsidiary, Caplin Steriles Limited (CSL) was granted approval from USFDA for its Phenylephrine Hydrochloride injection which is indicated to treat hypotension.

The company had incorporated its subsidiary CSL in FY19. The drug approved is for the power ranging of 10 mg/mL single-dose vial, 50 mg/5 mL (10mg/mL) pharmacy bulk package, and 100 mg/10 mL (10 mg/mL) pharmacy bulk package, a generic therapeutic equivalent version of (RLD), VAZCULEP injection, of Avadel Legacy Pharmaceuticals LLC. According to US sales data, approximately US$ 45 million worth of revenue was recorded in FY19.

This is the third hydrochloride-based drug which has been granted regulatory approval. This development certainly reflects signs of sustenance of the company during the economic slowdown. However, the management also stated that some of its products are seeing a shortage or are planned for emergency usage. The demand-supply would fetch priority levels accordingly.

The intra-day gains on Friday helped the stock to close at its high price on year-to-date basis. It closed on Rs 375.85, up by 7 per cent on BSE.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR